Precigen, Inc. (FRA:I5X)
Germany · Delayed Price · Currency is EUR | Market Cap | 1.13B +140.4% |
| Revenue (ttm) | 8.25M +146.7% |
| Net Income | -365.93M |
| EPS | -1.17 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 190 |
| Open | 3.336 |
| Previous Close | 3.336 |
| Day's Range | 3.336 - 3.336 |
| 52-Week Range | 1.007 - 4.552 |
| Beta | n/a |
| RSI | 56.19 |
| Earnings Date | Mar 25, 2026 |
About Precigen
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops pro... [Read more]
Financial Performance
In 2025, Precigen's revenue was $9.68 million, an increase of 146.73% compared to the previous year's $3.93 million. Losses were -$429.64 million, 240.4% more than in 2024.
Financial numbers in USD Financial StatementsNews
Precigen: The Best Potential Blockbuster You've Never Heard Of (Your ENT Has)
Precigen maintains a Buy rating as Papzimeos' strong launch and FDA approval signal blockbuster potential, with Q1 revenues expected to exceed $18M. PGEN's management guides for cash flow breakeven in...
These Analysts Boost Their Forecasts On Precigen Following Q4 Results
Precigen, Inc. (NASDAQ: PGEN) reported mixed results for the fourth quarter on Wednesday.
Precigen, Inc. (PGEN) Q4 2025 Earnings Call Transcript
Precigen, Inc. (PGEN) Q4 2025 Earnings Call Transcript
Precigen Reports Full Year 2025 Financial Results and Business Updates
Precigen transitioned to a commercial stage company with the US approval of PAPZIMEOS™ (zopapogene imadenovec-drba), the first-and-only FDA-approved treatment for adults with RRP, in August 2025 PAPZI...
Precigen to Announce Full Year 2025 Financial Results and Provide Business Updates on March 25
GERMANTOWN, Md., March 11, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve...
Precigen: PAPZIMEOS Is Delivering For This Under-The-Radar Biotech
Precigen: PAPZIMEOS Is Delivering For This Under-The-Radar Biotech
New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis
Independent, expert-led consensus paper, sponsored by the Recurrent Respiratory Papillomatosis Foundation, reflects the recommendation of 16 leading physicians in the field of RRP Consensus paper reco...
Precigen, Inc. (PGEN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Precigen, Inc. (PGEN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference
Precigen transitioned to a commercial stage company with the US approval of PAPZIMEOS in August 2025, the first-and-only FDA-approved treatment for adults with RRP PAPZIMEOS commercialization is well ...
Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference
GERMANTOWN, Md., Jan. 5, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company advancing innovative precision medicines, today announced that Helen Sabzevari, PhD, President ...
Precigen Is Still A Buy After The Papzimeos Rally
Precigen (PGEN) remains a Buy after PAPZIMEOS' FDA approval and launch, with higher-than-expected pricing and broad label supporting robust revenue potential. A new Pharmakon credit facility extends P...
Precigen, Inc. (PGEN) Q3 2025 Earnings Call Transcript
Precigen, Inc. ( PGEN) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Steven Harasym - VP & Head of Investor Relations Helen Sabzevari - President, CEO & Director Phil Tenna...
Precigen Reports Third Quarter 2025 Financial Results and Business Updates
PAPZIMEOS (zopapogene imadenovec-drba) received full approval by the FDA in August PAPZIMEOS launched with a broad label in the US as the first and only FDA-approved treatment for adults with RRP PAPZ...
Precigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13
GERMANTOWN, Md. , Nov. 6, 2025 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of pati...
Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis
15 out of 18 complete responders (83%) demonstrate continued complete response with median follow-up of 36 months Reduction in surgeries compared to year prior to treatment with PAPZIMEOS was observed...
Precigen Announces Up to $125 Million Non-Dilutive Financing
$100 million funded at close fortifies balance sheet and supports robust US commercialization of PAPZIMEOS, as well as potential expansion into international markets and the pursuit of pediatric and o...
Precigen, Inc. - Special Call
Precigen, Inc. - Special Call Company Participants Helen Sabzevari - President, CEO & Director Phil Tennant - Chief Commercial Officer Conference Call Participants Swayampakula Ramakanth - H.C. Wainwr...
Precigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright
GERMANTOWN, Md. , Aug. 25, 2025 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of pat...
Undercovered Dozen: Precigen, ONEOK, Bitmine And More
This week's Undercovered Dozen highlights 12 lesser-known stocks and ETFs with compelling investment theses and recent catalysts. Standouts include CGDV's market-beating performance, DIVO's retirement...
Precigen: This Billion-Dollar Approval Is Still Undervalued
PAPZIMEOS's full FDA approval for RRP is a decisive, de-risking event and validates Precigen's immunotherapy platform. PAPZIMEOS targets a significant unmet need, with potential for $1B+ peak sales, t...
Why Is Precigen Stock Surging On Friday?
On Friday, the U.S. Food and Drug Administration (FDA) approved Precigen Inc.'s PGEN Papzimeos (zopapogene imadenovec-drba) for adult patients with recurrent respiratory papillomatosis (RRP).
US FDA approves Precigen's immunotherapy for rare respiratory disease
The U.S. Food and Drug Administration has approved Precigen's immunotherapy to treat adults with a rare respiratory disease, making it the first treatment for the condition to receive the health regul...
Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis
PAPZIMEOS approval marks a historic milestone for the RRP patient community as the first and only FDA-approved therapy for the treatment of adults with RRP PAPZIMEOS received full approval from the FD...
Precigen: August Is Pivotal For This Biotech Innovator
Precigen's future hinges on the FDA's approval of PRGN-2012, with a pivotal decision expected August 27, 2025. PRGN-2012 shows strong efficacy and safety, potentially transforming the treatment of Rec...
Precigen Reports First Quarter 2025 Financial Results and Business Updates
PRGN-2012 has the potential to be the first- and best-in-class treatment for RRP Company's BLA for PRGN-2012 for the treatment of adults with RRP is under priority review by the FDA with a PDUFA targe...